Straits Times Index
3,338.57 +5.77 (+0.17%) S&P 500
5,475.09 +14.61 (+0.27%) Dow
39,169.52 +50.66 (+0.13%) Nasdaq
17,879.30 +146.70 (+0.83%) Bitcoin USD
62,906.42 +710.12 (+1.14%) CMC Crypto 200
1,347.26 +45.19 (+3.47%)
VERV Jul 2024 7.500 call
- GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on June 28, 2024, the company granted equity awards to one new employee, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c
- GlobeNewswire
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board of directors. Dr. Tatsis currently serves as executive vice president, chief regulatory and quality officer, of Vertex Pharmaceuticals. Ms. Morrison currently serves as chief executive officer and director
- Simply Wall St.
One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
Viewing insider transactions for Verve Therapeutics, Inc.'s ( NASDAQ:VERV ) over the last year, we see that insiders...
